Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New indication: Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma
Study: Randomized, open-label phase 3 trial (LYSA) Previously untreated low-burden Follicular lymphoma SOC (n=102) vs. Rituximab sc (n=100) Efficacy: CR: 36.3% vs. 59.0%, p=0.001 4-year PFS: 41.2% vs.58.1%, p=0.008 4-year
New Drug: Pirtobrutinib for relapsed or refractory mantle cell lymphoma
Study: Open-label, multicenter, single-arm trial (BRUIN) Mantle cell lymphoma previously treated with a BTK inhibitor Pirtobrutinib (n=120) Efficacy: ORR: 50% [41-59] DoR: 8.3 mos [5.7 mos-NR] 6 mos DoR: 65.3%
New Drug: Mosunetuzumab in patients with relapsed or refractory follicular lymphoma
Study: Single-arm, multicenter, phase 2 study Relapsed or refractory to two or more previous lines of treatment Mosunetuzumab q21 days (n=90) Efficacy: ORR: 80.0% [70·3–87·7; 72 of 90 pts] CR:
New Protocol – A Phase 2 Study of Pemigatinib in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement 8 (FIGHT-203)
Study: Phase 2, open label, multicenter trial Myeloid/Lymphoid Neoplasms 28 patients ≥1 prior therapy Pemigatinib 13.5 mg daily (2 wks; 1 wk off) No prior therapy Pemigatinib 13.5
New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Study: Randomised, triple-blind, phase 3 trial Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles Efficacy:
New Protocol: Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma
Study: Open-label, single-center, phase II study Previously untreated non-GCB DLBCL 60 patients Rituximab 375 mg/m2 (D1), lenalidomide 25 mg D(1-10), and ibrutinib 560 mg continuously (RLI) after two cycles, 6
New Reference: Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Study: Multicenter, randomized, open-label trial Stage 3 or 4 advanced Hodgkin’s lymphoma A+AVD (n:664) or ABVD (n:670) Efficacy: OS favored A+AVD over ABVD (HR: 0.59; P=0.009) 6 year OS: 93.9%
New Reference: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Study: Phase 3, open label, randomized study (RELEVANCE) Untreated grade 1-3a FL R2 (n:513) or R-chemo (n:517), followed by rituximab maintenance Efficacy: ORR: 61% and 65%, CR/CRu: 48% and 53%